|
【结 构 式】 
|
【分子编号】39377 【品名】2-[(3S)-3-[(tert-butoxycarbonyl)amino]-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetic acid 【CA登记号】 |
【 分 子 式 】C17H22N2O5S 【 分 子 量 】366.43816 【元素组成】C 55.72% H 6.05% N 7.64% O 21.83% S 8.75% |
合成路线1
该中间体在本合成路线中的序号：(X)Alkylation of N-acetyl-D-cysteine (I) with 1-fluoro-5-methyl-2-nitrobenzene (II) gave adduct (III). After hydrolysis of the acetamido group of (III) with aqueous sulfuric acid, the resulting amine (IV) was protected as the benzyl carbamate (V). Reduction of the nitro group of (V) provided amino acid (VI), which was cyclized to the benzothiazepinone (VII) using EDC. Subsequent alkylation of (VII) with ethyl bromoacetate under phase-transfer conditions yielded (VIII) (1). Cleavage of both N-Cbz group and ethyl ester by HBr in AcOH, followed by introduction of the N-Boc group afforded intermediate (X) (2). Optionally, hydrogenolysis of the N-Cbz group of (VIII) provided amino lactam (XI). This was coupled with N-Boc-O-benzylserine (XII) to give amide (XIII). Then, basic hydrolysis of the ethyl ester produced carboxylic acid (XIV).
| 【1】 Dodey, P.; Luccarini, J.-M.; Martinez, J.; Amblard, M.; Daffix, I. (Fournier Industrie et Santé); Peptides agonists of bradykinine B2 receptor. FR 2756566; WO 9824809 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| 10101 | Benzyloxycarbonyl chloride; Benzyl chloroformate; 1-[[(Chlorocarbonyl)oxy]methyl]benzene | 501-53-1 | C8H7ClO2 | 详情 | 详情 | |
| 16640 | Ethyl 2-bromoacetate; Ethyl bromoacetate | 105-36-2 | C4H7BrO2 | 详情 | 详情 | |
| (I) | 39365 | (2S)-2-(acetamido)-3-sulfanylpropionic acid | 616-91-1 | C5H9NO3S | 详情 | 详情 |
| (II) | 39366 | 2-fluoro-4-methyl-1-nitrobenzene | 446-34-4 | C7H6FNO2 | 详情 | 详情 |
| (III) | 39367 | (2S)-2-(acetamido)-3-[(5-methyl-2-nitrophenyl)sulfanyl]propionic acid | C12H14N2O5S | 详情 | 详情 | |
| (IV) | 39368 | (2S)-2-amino-3-[(5-methyl-2-nitrophenyl)sulfanyl]propionic acid | C10H12N2O4S | 详情 | 详情 | |
| (V) | 39369 | (2S)-2-[[(benzyloxy)carbonyl]amino]-3-[(5-methyl-2-nitrophenyl)sulfanyl]propionic acid | C18H18N2O6S | 详情 | 详情 | |
| (VI) | 39370 | (2S)-3-[(2-amino-5-methylphenyl)sulfanyl]-2-[[(benzyloxy)carbonyl]amino]propionic acid | C18H20N2O4S | 详情 | 详情 | |
| (VII) | 39371 | benzyl (3S)-8-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-ylcarbamate | C18H18N2O3S | 详情 | 详情 | |
| (VIII) | 39372 | ethyl 2-[(3S)-3-[[(benzyloxy)carbonyl]amino]-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetate | C22H24N2O5S | 详情 | 详情 | |
| (IX) | 39376 | 2-[(3S)-3-amino-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetic acid | C12H14N2O3S | 详情 | 详情 | |
| (X) | 39377 | 2-[(3S)-3-[(tert-butoxycarbonyl)amino]-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetic acid | C17H22N2O5S | 详情 | 详情 | |
| (XI) | 39373 | ethyl 2-[(3S)-3-amino-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetate | C14H18N2O3S | 详情 | 详情 | |
| (XII) | 16886 | (2S)-3-(benzyloxy)-2-[(tert-butoxycarbonyl)amino]propionic acid; N-alpha-t-BOC-o-benzyl-L-serine | 23680-31-1 | C15H21NO5 | 详情 | 详情 |
| (XIII) | 39374 | ethyl 2-[(3S)-3-([(2S)-3-(benzyloxy)-2-[(tert-butoxycarbonyl)amino]propanoyl]amino)-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetate | C29H37N3O7S | 详情 | 详情 | |
| (XIV) | 39375 | 2-[(3S)-3-([(2S)-3-(benzyloxy)-2-[(tert-butoxycarbonyl)amino]propanoyl]amino)-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetic acid | C27H33N3O7S | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(X)Construction of the peptide chain was carried out by solid phase synthesis on a Merrifield resin. The protected arginine bound to the resin (XV) was treated with trifluoroacetic to cleave the N-Boc group. The resulting NG-arginine-resin (XVI) was coupled with benzothiazepineacetic acid (X) by means of BOP reagent to produce (XVII). After deprotection of the Boc group of (XVII) with trifluoroacetic acid, further coupling with protected serine (XII) gave peptide resin (XIX). The Boc group of (XIX) was then deprotected with trifluoroacetic acid as above to furnish intermediate (XX).
| 【1】 Daffix, I.; Bergé, G.; Amblard, M.; et al.; Synthesis and characterization of bradykinin B2 receptor agonists containing constrained dipeptide mimics. J Med Chem 1999, 42, 20, 4193. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (X) | 39377 | 2-[(3S)-3-[(tert-butoxycarbonyl)amino]-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetic acid | C17H22N2O5S | 详情 | 详情 | |
| (XII) | 16886 | (2S)-3-(benzyloxy)-2-[(tert-butoxycarbonyl)amino]propionic acid; N-alpha-t-BOC-o-benzyl-L-serine | 23680-31-1 | C15H21NO5 | 详情 | 详情 |
| (XV) | 39378 | (2S)-5-[(amino[[(4-methylphenyl)sulfonyl]imino]methyl)amino]-2-[(tert-butoxycarbonyl)amino]pentanoic acid | C18H28N4O6S | 详情 | 详情 | |
| (XVI) | 39379 | (2S)-2-amino-5-[(amino[[(4-methylphenyl)sulfonyl]imino]methyl)amino]pentanoic acid | C13H20N4O4S | 详情 | 详情 | |
| (XVII) | 39380 | (2S)-5-[(amino[[(4-methylphenyl)sulfonyl]imino]methyl)amino]-2-([2-[(3S)-3-[(tert-butoxycarbonyl)amino]-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetyl]amino)pentanoic acid | C30H40N6O8S2 | 详情 | 详情 | |
| (XVIII) | 39381 | (2S)-2-([2-[(3S)-3-amino-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetyl]amino)-5-[(amino[[(4-methylphenyl)sulfonyl]imino]methyl)amino]pentanoic acid | C25H32N6O6S2 | 详情 | 详情 | |
| (XIX) | 39382 | (2S)-5-[(amino[[(4-methylphenyl)sulfonyl]imino]methyl)amino]-2-([2-[(3S)-3-([(2S)-3-(benzyloxy)-2-[(tert-butoxycarbonyl)amino]propanoyl]amino)-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetyl]amino)pentanoic acid | C40H51N7O10S2 | 详情 | 详情 | |
| (XX) | 39383 | (2S)-2-([2-[(3S)-3-[[(2S)-2-amino-3-(benzyloxy)propanoyl]amino]-8-methyl-4-oxo-3,4-dihydro-1,5-benzothiazepin-5(2H)-yl]acetyl]amino)-5-[(amino[[(4-methylphenyl)sulfonyl]imino]methyl)amino]pentanoic acid | C35H43N7O8S2 | 详情 | 详情 |